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Cystic fibrosis (CF) is a serious autosomal recessive disorder that 
occurs with varying frequency in all population groups throughout 
the world, including South Africa (SA). Although CF survival has 
improved over the past two decades, it remains a life-shortening 
condition with median survival age now reported in the USA to be 
~40 years.[1] Despite early pioneering work relating to the molecular 
diagnosis of CF in SA,[2] little is known of the current prevalence, 
clinical spectrum and outcomes of CF in the SA population, which 
has wide ethnic and genetic diversity. Data from 2005 from the 
Red Cross War Memorial Children’s Hospital CF clinic cohort in 
Cape Town indicated that the median age of diagnosis and survival 
age during the preceding 33 years were 6 months and 19.8 years, 
respectively.[3] Absence of newborn screening, limited access to 
sweat testing for diagnosis and restricted availability of expensive CF 
medications (such as inhaled rhDNAse) or lung transplantation are 
barriers to improving CF survival in SA. Early and accurate diagnosis 
and understanding the epidemiology of CF in SA are important to 
improve outcomes and inform health intervention policies.
In order to address the limitations in CF diagnostic capacity and 
care in SA, the South African Cystic Fibrosis Medical and Scientific 
Advisory Committee (MSAC) wishes to draw the attention of the 
readership of the SAMJ to a few important local and international 
advancements in the field of CF.
The South African Cystic Fibrosis 
Consensus Guidelines: 5th revision, 
2017
The MSAC, in partnership with the South African Cystic Fibrosis 
Association (SACFA), has revised and published the 5th edition 
of these guidelines, which comprehensively cover all aspects of 
CF diagnosis and management appropriate to the SA setting. The 
guidelines are freely available on the SACFA website (http://www.
sacfa.org.za/wp-content/uploads/2017_09_14_CF_Consensus_
Guidelines_2017.pdf).[4] We wish to highlight a few important new 
concepts that appear in this latest revision.
Diagnosis of CF
Molecular diagnosis
The diagnosis of classic or typical CF is confirmed by a positive sweat 
test (sweat chloride >60 mmol/L) and/or the identification of two 
disease-causing CFTR (cystic fibrosis transmembrane conductance 
regulator) mutations on DNA analysis. Over 2 000 CFTR mutations, 
now classified into six distinct functional classes, have been described 
to date, of which ~200 are classified as ‘disease causing’. The 
Cystic Fibrosis Foundation’s updated consensus statement on CF 
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Cystic fibrosis in South Africa across the spectrum:  normal health, growth 
and development can be achieved with early diagnosis and close monitoring 
by specialist teams. (Photo: Brenda Morrow. Permission to publish this photo 
was obtained from the children and their parents.)
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diagnosis recommends the following broad 
classification of CFTR mutations and has 
adopted the CFTR2 database (https://www.
cftr2.org/index.php) as its reference:[5] 
• CF-causing mutation: results in CF when 
two abnormal alleles are present in an 
individual
• Mutation of varying clinical consequence 
(MVCC): a mutation that in combination 
with a CF-causing mutation or another 
MVCC may result in CF
• Mutation of unknown clinical conse-
quence: not evaluated by CFTR2
• Non-CF-causing mutation.
The recognition that the inheritance of any 
combination of CFTR mutations will result 
in a wide spectrum of CF phenotypes is 
important. Healthcare providers are advised 
to refer to the CFTR2 database to establish 
the clinical significance of CFTR mutations 
that are identified. Consultation with a CF 
expert and a genetic counsellor is strongly 
recommended when a CFTR mutation is 
identified.
Commercially available CFTR genotype 
panels available in SA can detect up to 50 
known CFTR mutations prevalent in the 
SA population. Included in this panel is 
p.Phe508del (previously known as ∆F508), 
the most common mutation in Caucasian 
and mixed-race people, and c.2988+1G>A 
(previously known as 3120+1G>A), the 
most common mutation in black African 
people. This approach is unsuitable for 
the SA setting, however, as 79% of black 
Africans, 55% of individuals of mixed race 
and 17% of Caucasians will need further 
molecular testing to confirm a diagnosis 
of CF.[2] The high proportion of unknown 
mutations, especially in non-Caucasians 
with CF, reflects the ethnic and genetic 
diversity in the SA population. There are 
few data from the African continent, but 
a survey identifying disease-causing CF 
mutations in people of African descent in 
the Americas found that 55% of alleles still 
remained unidentified.[6]
Next-generation sequencing (NGS) tech-
nol ogy, which screens the whole CFTR gene 
for abnormal alleles, is becoming more 
accessible and affordable in SA. Although 
much more powerful than genotyping 
for detecting CFTR variants, NGS has 
limitations that relate to interpretation of the 
clinical significance of detected mutations, 
many of which can be expected to be 
novel in SA population. The optimal and 
most cost-effective approach and strategy 
to molecular confirmation of CF in SA 
is under investigation. Further research 
employing NGS is needed to define the 
complete spectrum of CFTR variants in the 
SA population.
Sweat test reference ranges
A sweat chloride concentration >60 mmol/L 
is the hallmark of typical or classic CF. 
Abnormal CFTR function in sweat 
glands manifests as impaired salt (NaCl) 
reabsorption and is the physiological basis 
of the sweat test. The recognition of milder 
or atypical forms of CF associated with mild 
CFTR mutations and residual CFTR function 
has led to revision by the International 
Cystic Fibrosis Foundation of the lower limit 
of the sweat chloride reference range in the 
intermediate zone to 30 mmol/L for all ages 
(previously 40 mmol/L) (Table 1).[5]
Sweat conductivity is another diagnostic 
test commonly performed in SA and in 
some circumstances the only type of ‘sweat 
test’ available. It is important that clinicians 
understand the difference between sweat 
chloride concentration and sweat conduc-
tivity. Sweat conductivity measures 
the NaCl equivalent concentration of 
all ionised molecules in sweat, not only 
chloride. Sweat conductivity is therefore 
on average 15 - 20 mmol/L higher than the 
equivalent sweat chloride concentration. 
Sweat conductivity is widely accepted as 
a good screening test for CF and levels of 
>50 mmol/L should be followed up with 
measurement of sweat chloride. In most 
cases of typical CF, sweat conductivity levels 
Table 1. Reference ranges for sweat chloride and sweat conductivity
Sweat test interpretation Sweat chloride (mmol/L) Sweat conductivity (NaCl equivalent, mmol/L)
Positive, CF likely >60 >80
Intermediate, CF possible 30 - 59 40 - 79
Negative, CF unlikely <30 <40
CF = cystic fibrosis.
SUSPECT CF
Sweat chloride or conductivity testing
Cl <29 mmol/L
Conductivity <40 mmol/L
2 CFTR mutations
Consider CFTR 
dysfunction/CF 
carrier/not CF
Refer to CF centre
Cl 30 - 59 mmol/L
Conductivity 41 - 79 mmol/L
INTERMEDIATE RANGE
Cl >60 mmol/L
Conductivity >80 mmol/L
CF unlikely CFTR testing CF likely
No or 1 CFTR mutation CFTR and faecal 
elastase testing
Atypical CF
Refer to CF centre
Follow up closely
Fig. 1. Diagnostic algorithm for CF where sweat testing is available (from the South African Cystic 
Fibrosis Consensus Guidelines, 5th ed.[4]). (CF = cystic fibrosis; CFTR = cystic fibrosis transmembrane 
conductance regulator.)
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are conclusively positive. However, in mild 
or atypical CF, clear reference ranges for 
conductivity levels are lacking and may lead 
to misdiagnosis of CF. The MSAC therefore 
strongly recommends that all laboratory 
services in SA measure and report only 
sweat chloride, and use conductivity just as 
a screening tool. In circumstances where 
sweat testing is not available, the MSAC 
recommends measuring faecal elastase as 
a screening test for pancreatic-insufficient 
(PI) CF, which occurs in 80 - 85% of all 
CF cases. A normal faecal elastase level 
therefore does not exclude pancreatic-
sufficient CF. Where PI CF is confirmed, 
or there is strong clinical suspicion of CF, 
collecting a blood sample for DNA testing is 
recommended. As faecal elastase or genetic 
results may take several weeks to return, 
we strongly advise clinicians to empirically 
commence pancreatic enzyme replacement 
therapy and other CF-related interventions 
while waiting for these results if the 
clinical suspicion of CF is high. Diagnostic 
algorithms for the diagnosis of CF in SA 
are shown in Figs 1 and 2. Furthermore, 
appropriate sibling and family screening 
through genetic counselling services 
is recommended in all people newly 
diagnosed with CF.
Novel CF treatments
Advances in the molecular biology of the 
CFTR molecule have identified six distinct 
classes of CFTR mutations, each associated 
with different causes and severity of CFTR 
dysfunction and phenotypic expression. [7] 
This has led to the development of 
breakthrough novel therapies that target the 
underlying CFTR defect at multiple levels, 
placing CF at the forefront of precision 
medicine.[7,8] Clinical trials of the CFTR 
modulator drugs ivacaftor, which targets the 
G551D mutation, and lumicafor/tezacaftor, 
which targets the p.Phe508del mutation, have 
reported mild to moderate beneficial effects 
in outcomes including pulmonary function, 
pulmonary exacerbations and nutrition.[9-11] 
The implications for identifying which CFTR 
mutations each person with CF carries now 
go beyond simply diagnosis and prognosis 
and include therapy.
Cautious optimism must be exercised 
with these new drugs, however. Ivacaftor, 
indicated for people who carry the G551D 
mutation (<5% of all people with CF), has 
shown the best clinical results. Recently 
published early phase 2 clinical trial results 
of two new-generation, small-molecule 
CFTR correctors, VX-445 and VX-659 
in triple combination with tezacaftor and 
ivacaftor (‘triple therapy‘), show promising 
results in people with two copies of 
p.Phe508del. [12,13] None of these drugs are 
currently registered and licensed in SA, 
and until the cost (currently USD300 000 
per annum) is substantially reduced, it is 
unlikely that medical schemes or the public 
health sector will fund these drugs in the 
near future. MSAC and the CF community 
are engaging with international pharma to 
advocate for affordable access to these new 
agents in SA.
The South African 
Cystic Fibrosis Registry 
Initiative (SACFRI).
In line with international practice, MSAC in 
partnership with the SACFA launched the 
SACFRI in April 2018. This initiative aims 
to document and monitor data relating to 
the diagnosis and outcomes of all people 
diagnosed with CF in SA. There is currently 
little knowledge on the number of individuals 
with CF in SA, or on their epidemiology or 
outcomes. Registry data are important and 
useful for many reasons, including: 
• Monitoring overall health outcomes and 
trends in CF care in order to detect deficits 
or areas of care that need intervention. By 
comparing our data with international 
trends, we can identify gaps in CF care 
that need attention.
• Keeping accurate statistics in SA will help 
us advocate for CF care to government 
and medical aids.
• Planning and conducting research that 
will benefit the CF community, including 
identifying individuals who may be eligible 
for clinical trials of new treatments.
We encourage medical practitioners and 
members of the CF community to inquire 
about SACFRI by contacting SACFA or their 
CF clinic or doctor. Appropriate precautions 
have been taken to ensure patient 
confidentiality and protection of medical 
and personal information, and approval has 
been obtained from local research ethics 
committees. Obtaining informed signed 
consent and assent from people with CF is 
a requirement for inclusion in the SACFRI 
database.
Although CF is still considered an incura-
ble disorder in 2019, significant advances in 
its diagnosis, care and treatment mean that 
CF, previously considered universally fatal 
in childhood, is now a chronic condition that 
SUSPECT CF
Faecal elastase testing
          <200 µg/g
High suspicion of PS 
or atypical CF*
Two CFTR
 mutations
PI CF conrmed
PS CF conrmed
Refer to CF centre Refer to CF centre Refer to CF centre Refer to CF centre
Low suspicion of PS CF CFTR testing
CFTR testing
One or no 
mutations
Two CFTR 
mutations
One or no 
mutations
CF unlikely
>200 µg/g 
Fig. 2. Recommended diagnostic algorithm where sweat testing is not available (from the South 
African Cystic Fibrosis Consensus Guidelines, 5th ed.[4]). (CF = cystic fibrosis; PS = pancreatic 
sufficient; PI = pancreatic insufficient; CFTR = cystic fibrosis transmembrane conductance regulator. 
*Male infertility due to congenital bilateral absence of vas deferens, chronic or recurrent pancreatitis, 
allergic bronchopulmonary aspergillosis, isolated bronchiectasis, diffuse panbronchiolitis, neonatal 
hypertrypsinoginaemia, severe recurrent sinusitis or nasal polyposis, sclerosing cholangitis.)
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must be managed optimally. People with CF should look forward to 
leading normal productive lives, provided early diagnosis and access 
to quality healthcare are in place. Healthcare workers, government 
and health funders have an obligation to ensure that people with 
CF in SA are not left behind by the advancements in CF care we are 
witnessing in the rest of the world.
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